Arbutus Biopharma Corp. Company Profile (NASDAQ:ABUS)

About Arbutus Biopharma Corp.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: ABUS
CUSIP:

Key Metrics:

Previous Close: $3.99
50 Day Moving Average: $3.79
200 Day Moving Average: $4.06
52-Week Range: $2.72 - $6.82
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -2.04
P/E Growth: 0.00
Market Cap: $218.64M
Outstanding Shares: 54,796,000
Beta: 1.12

Profitability:

Net Margins: -1,017.01%
Return on Equity: -8.87%
Return on Assets: -6.88%

Debt:

Current Ratio: 16.67%
Quick Ratio: 16.67%

Additional Links:

Companies Related to Arbutus Biopharma Corp.:

Consensus Ratings for Arbutus Biopharma Corp. (NASDAQ:ABUS) (?)

Ratings Breakdown:	1 Sell Rating, 1 Hold Rating, 3 Buy Ratings
Consensus Rating:	Hold (Score: 2.40)
Consensus Price Target:	$7.95 (99.25% upside)

Analysts' Ratings History for Arbutus Biopharma Corp. (NASDAQ:ABUS)

Show:

Date	Firm	Action	Rating	Price Target
9/23/2016	Wedbush	Reiterated Rating	Outperform	$13.00
8/21/2016	William Blair	Reiterated Rating	Outperform
8/17/2016	Leerink Swann	Downgrade	Outperform -> Market Perform
7/8/2016	Chardan Capital	Downgrade	Neutral -> Sell	$3.25 -> $2.75
12/21/2015	Royal Bank Of Canada	Lower Price Target		$20.00 -> $12.00
9/2/2015	JMP Securities	Initiated Coverage	Outperform	$13.00
6/16/2015	Maxim Group	Lower Price Target	Hold -> Buy	$27.00 -> $14.00
3/30/2015	Nomura	Initiated Coverage	Buy	$32.00
11/7/2014	Stifel Nicolaus	Reiterated Rating	Positive -> Buy	$31.00 -> $26.00

(Data available from 9/27/2014 forward)

Earnings History for Arbutus Biopharma Corp. (NASDAQ:ABUS)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/3/2016
8/4/2016	Q2	($0.39)	($0.75)			View	N/A
5/4/2016	Q1	($0.39)	($0.19)			View	N/A
3/9/2016	Q4	($0.41)	($0.06)			View	N/A
11/5/2015		($0.31)	($0.42)			View	N/A
8/5/2015	Q2	($0.26)	($0.20)			View	N/A
3/13/2015		($0.32)	($0.27)			View	N/A
11/6/2014	Q314	($0.31)	($0.39)	$3.71 million	$4.40 million	View	N/A
8/13/2014	Q214	($0.26)	($0.28)	$3.72 million	$1.80 million	View	N/A
12/18/2013	Q3	($0.07)	($0.12)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Arbutus Biopharma Corp. (NASDAQ:ABUS)

Current Year EPS Consensus Estimate: $-2.15 EPS
Next Year EPS Consensus Estimate: $-1.96 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	2	($0.38)	($0.36)	($0.37)
Q2 2016	2	($0.40)	($0.35)	($0.38)
Q3 2016	2	($0.41)	($0.39)	($0.40)
Q4 2016	2	($0.39)	($0.36)	($0.38)
Q1 2017	1	($0.66)	($0.66)	($0.66)
Q2 2017	1	($0.69)	($0.69)	($0.69)
Q3 2017	1	($0.71)	($0.71)	($0.71)
Q4 2017	1	($0.73)	($0.73)	($0.73)

(Data provided by Zacks Investment Research)

Dividend History for Arbutus Biopharma Corp. (NASDAQ:ABUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Arbutus Biopharma Corp. (NASDAQ:ABUS)

Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 31.87%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Details
8/24/2015	Richard C Henriques Jr	Director	Buy	1,000	$6.95	$6,950.00

(Data available from 1/1/2013 forward)

Latest Headlines for Arbutus Biopharma Corp. (NASDAQ:ABUS)

Date	Headline
	What Next for Arbutus Biopharma Corp Stock After Today's Huge Increase? - Post News (NASDAQ:ABUS) www.kentuckypostnews.com - September 21 at 11:13 AM
	Arbutus Biopharma Corporation (NASDAQ:ABUS) Sellers Increased By 1.37% Their Shorts - Frisco Fastball (NASDAQ:ABUS) friscofastball.com - September 14 at 3:15 PM
	Arbutus Biopharma Corporation (NASDAQ:ABUS) Sellers Increased By 1.37% Their Shorts - Frisco Fastball (NASDAQ:ABUS) friscofastball.com - September 14 at 3:15 PM
	Placing Arbutus Biopharma Corp (NASDAQ:ABUS) Shares Under the Microscope - Post News (NASDAQ:ABUS) www.kentuckypostnews.com - September 7 at 8:24 PM
	Stock Tracker: Earnings & Estimates for Arbutus Biopharma Corp (NASDAQ:ABUS) - Frisco Fastball (NASDAQ:ABUS) friscofastball.com - September 7 at 8:24 PM
	Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2016 Update (NASDAQ:ABUS) seekingalpha.com - August 22 at 8:03 AM
	ARBUTUS BIOPHARMA CORP : Entry into a Material Definitive Agreement (form 8-K) (NASDAQ:ABUS) www.4-traders.com - August 20 at 3:17 PM
	Major tenant leaving Pa. Biotechnology Center for more space in Warminster (NASDAQ:ABUS) www.bizjournals.com - August 19 at 8:16 PM
	Crowd is Weighing in on Arbutus Biopharma Corp (NASDAQ:ABUS) - Post News (NASDAQ:ABUS) www.kentuckypostnews.com - August 17 at 3:16 PM
	Arbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:ABUS) www.capitalcube.com - August 15 at 3:17 PM
	Should You Get Rid of Arbutus Biopharma (ABUS) Now? (NASDAQ:ABUS) finance.yahoo.com - August 12 at 11:48 AM
	Analysts Downgrades Report: Arbutus Biopharma Corp (NASDAQ:ABUS) - Review Fortune (NASDAQ:ABUS) reviewfortune.com - August 10 at 11:49 AM
	4:35 pm Arbutus Biopharma announces the issuance of a new patent for its proprietary lipid nanoparticle delivery technology (NASDAQ:ABUS) finance.yahoo.com - August 8 at 8:43 PM
	Arbutus Announces Issuance of Broad New US Patent for LNP Delivery Technology (NASDAQ:ABUS) www.publicnow.com - August 8 at 8:43 PM
	Arbutus reports 2Q loss (NASDAQ:ABUS) sg.finance.yahoo.com - August 5 at 11:37 AM
	Arbutus Provides Corporate Update and Announces Second Quarter 2016 Financial Results (NASDAQ:ABUS) www.publicnow.com - August 4 at 8:58 PM
	Kinder Morgan, Inc. (NYSE:KMI) rose 0.54%: Arbutus Biopharma Corporation (NASDAQ:ABUS), BCE Inc. (NYSE:BCE ... - KC Register (NASDAQ:ABUS) www.kcregister.com - August 1 at 3:15 PM
	Arbutus Biopharma Corporation (NASDAQ:ABUS) fell -2.61%, International Business Machines Corporation (NYSE ... - KC Register (NASDAQ:ABUS) www.kcregister.com - July 27 at 3:18 PM
	Arbutus Biopharma Corp (NASDAQ:ABUS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:ABUS) www.engelwooddaily.com - July 22 at 11:25 AM
	Equity Roundup: Stock Performance Focus on Arbutus Biopharma Corp (NASDAQ:ABUS) - Press Telegraph (NASDAQ:ABUS) presstelegraph.com - July 21 at 3:15 PM
	Broker Outlook For Arbutus Biopharma Corporation (NASDAQ:ABUS) - Fiscal Standard (NASDAQ:ABUS) www.fiscalstandard.com - July 21 at 11:29 AM
	Earnings Focus and Crowd Sourced Sentiment Review for Arbutus Biopharma Corp (NASDAQ:ABUS) - TGP (NASDAQ:ABUS) telanaganapress.com - July 20 at 11:24 AM
	Arbutus Biopharma (ABUS) Says TKM-PLK1 Well-Tolerated in Phase I/II Trial - StreetInsider.com (NASDAQ:ABUS) www.streetinsider.com - July 20 at 11:24 AM
	Arbutus Reports Topline Results from TKM-PLK1 HCC Clinical Trial (NASDAQ:ABUS) www.4-traders.com - July 19 at 8:42 PM
	Arbutus Biopharma Corporation (NASDAQ:ABUS) Shorted Shares Decreased By 8.15% - Consumer Eagle (NASDAQ:ABUS) www.consumereagle.com - July 16 at 3:15 PM
	Analyst Target and Average Rating Watch: Arbutus Biopharma Corp (NASDAQ:ABUS) - Press Telegraph (NASDAQ:ABUS) presstelegraph.com - July 15 at 7:30 PM
	Arbutus Biopharma Corp (NASDAQ:ABUS) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:ABUS) www.engelwooddaily.com - July 15 at 7:30 PM
	Trading Performance and Target Watch for Arbutus Biopharma Corp (NASDAQ:ABUS) - Press Telegraph (NASDAQ:ABUS) presstelegraph.com - July 14 at 8:44 PM
	Andreas Halvorsen's Viking Global Gets Control of Stakes in 2 Companies for Backing Hot Biotech (NASDAQ:ABUS) finance.yahoo.com - July 14 at 7:20 PM
	Chardan Capital Downgrades Arbutus Biopharma Corp to Sell - TheFounders Daily (NASDAQ:ABUS) www.thefoundersdaily.com - July 14 at 3:15 PM
	Arbutus Biopharma Corporation Realized Volatility Hits Extreme Level - CML News (NASDAQ:ABUS) news.cmlviz.com - July 14 at 3:15 PM
	Roivant Sciences Appoints Professor Andrew Lo, PhD as Independent Director (NASDAQ:ABUS) finance.yahoo.com - July 13 at 4:01 PM
	Arbutus Biopharma Corp (NASDAQ:ABUS) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:ABUS) telanaganapress.com - July 12 at 8:44 PM
	Stock Rating Watch and Earnings Insight for Arbutus Biopharma Corp (NASDAQ:ABUS) - Press Telegraph (NASDAQ:ABUS) presstelegraph.com - July 11 at 8:02 AM
	Arbutus Biopharma Corporation (NASDAQ:ABUS) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:ABUS) www.fiscalstandard.com - July 10 at 3:15 PM
	Arbutus Biopharma Corporation (NASDAQ:ABUS) Sellers Covered 8.15% of Their Shorts - Press Telegraph (NASDAQ:ABUS) presstelegraph.com - July 9 at 11:22 AM
	Company Stock Focus for Arbutus Biopharma Corp (NASDAQ:ABUS): Which Way Will Shares Head? - Press Telegraph (NASDAQ:ABUS) presstelegraph.com - July 8 at 3:16 PM
	Arbutus Biopharma Corporation Stock Momentum at Critical Inflection Point - CML News (NASDAQ:ABUS) news.cmlviz.com - July 7 at 3:15 PM
	Arbutus Biopharma Corp (NASDAQ:ABUS) Stock Update: Check on Ratings and Target Price - Telanagana Press (NASDAQ:ABUS) telanaganapress.com - July 6 at 8:02 AM
	Eye Catching Stocks: Arbutus Biopharma Corporation (NASDAQ:ABUS), Facebook Inc (NASDAQ:FB), Organovo ... - KC Register (NASDAQ:ABUS) www.kcregister.com - July 5 at 8:02 AM
	Does Arbutus Biopharma Corp Have Any Gas After Today's Huge Increase? - Press Telegraph (NASDAQ:ABUS) presstelegraph.com - July 4 at 3:15 PM
	Arbutus Biopharma Corp (NASDAQ:ABUS) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:ABUS) www.engelwooddaily.com - July 1 at 8:29 PM
	Covering the Bases on Arbutus Biopharma Corp (NASDAQ:ABUS): Where is the Stock Going? - Press Telegraph (NASDAQ:ABUS) presstelegraph.com - July 1 at 8:29 PM
	Arbutus Biopharma Corporation (NASDAQ:ABUS) Updated Price Targets - FTSE News (NASDAQ:ABUS) www.ftsenews.co.uk - July 1 at 3:15 PM
	Tekmira Pharmaceuticals Corporation: Arbutus to Present mRNA Delivery Data at the 32nd Annual Meeting of the ... - The Wall Street Transcript (NASDAQ:ABUS) www.twst.com - June 30 at 3:15 PM
	ARBUTUS BIOPHARMA CORP Files SEC form 8-K, Other Events (NASDAQ:ABUS) biz.yahoo.com - June 30 at 8:01 AM
	Arbutus to Present mRNA Delivery Data at the 32nd Annual Meeting of the Japan Society of Drug Delivery System (NASDAQ:ABUS) finance.yahoo.com - June 30 at 8:00 AM
	Recently Issued Stock Ratings For Arbutus Biopharma Corporation (NASDAQ:ABUS) - Fiscal Standard (NASDAQ:ABUS) www.fiscalstandard.com - June 29 at 3:14 PM
	Arbutus Biopharma Corporation (NASDAQ:ABUS) Sellers Covered 8.15% of Their Shorts - Engelwood Daily (NASDAQ:ABUS) www.engelwooddaily.com - June 29 at 11:10 AM
	Chardan Capital Upgrades Arbutus Biopharma Corp to Neutral with Price Target $3.25 - TheFounders Daily (NASDAQ:ABUS) www.thefoundersdaily.com - June 25 at 11:19 AM